These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 15389794)
21. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043 [TBL] [Abstract][Full Text] [Related]
22. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Zaks TZ; Rosenberg SA Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997 [TBL] [Abstract][Full Text] [Related]
23. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy. Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380 [TBL] [Abstract][Full Text] [Related]
24. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728 [TBL] [Abstract][Full Text] [Related]
25. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460 [TBL] [Abstract][Full Text] [Related]
26. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526 [TBL] [Abstract][Full Text] [Related]
27. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer. Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796 [TBL] [Abstract][Full Text] [Related]
28. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
29. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572 [TBL] [Abstract][Full Text] [Related]
30. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner. Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688 [TBL] [Abstract][Full Text] [Related]
31. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247 [TBL] [Abstract][Full Text] [Related]
32. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18. Castellanos MR; Hayes RL; Maiman MA Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965 [TBL] [Abstract][Full Text] [Related]
33. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Kiessling A; Füssel S; Schmitz M; Stevanovic S; Meye A; Weigle B; Klenk U; Wirth MP; Rieber EP Prostate; 2003 Sep; 56(4):270-9. PubMed ID: 12858355 [TBL] [Abstract][Full Text] [Related]
34. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer. Hara M; Matsueda S; Tamura M; Takedatsu H; Tanaka M; Kawano K; Mochizuki K; Kamura T; Itoh K; Harada M Int J Oncol; 2005 Nov; 27(5):1371-9. PubMed ID: 16211234 [TBL] [Abstract][Full Text] [Related]
35. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro. Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945 [TBL] [Abstract][Full Text] [Related]
36. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. Inoue Y; Takaue Y; Takei M; Kato K; Kanai S; Harada Y; Tobisu K; Noguchi M; Kakizoe T; Itoh K; Wakasugi H J Urol; 2001 Oct; 166(4):1508-13. PubMed ID: 11547122 [TBL] [Abstract][Full Text] [Related]
37. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma. Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241 [TBL] [Abstract][Full Text] [Related]
38. Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types. Arima Y; Matsueda S; Yano H; Harada M; Itoh K Int J Oncol; 2005 Oct; 27(4):981-8. PubMed ID: 16142314 [TBL] [Abstract][Full Text] [Related]
39. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Azuma K; Shichijo S; Maeda Y; Nakatsura T; Nonaka Y; Fujii T; Koike K; Itoh K Cancer Res; 2003 Feb; 63(4):854-8. PubMed ID: 12591737 [TBL] [Abstract][Full Text] [Related]
40. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]